Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31749819 | 1.00 | MDM2 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL8059732 | 1.00 | MDM2 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL27337389 | 0.96 | MDM2 (0.52) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL29398330 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL31714219 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL29399025 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL8035574 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL24810743 | 0.92 | MDM2 (0.47) | MDM2MDM4TP53TNFCASP3 | |
| SCHEMBL6856061 | 0.88 | MDM2 (0.46) | MDM2MDM4TP53CASP3TLR2 | |
| SCHEMBL6855718 | 0.88 | MDM2 (0.46) | MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | disclosed |
| CN-117858948-A | Novel therapeutic agent delivery moieties and uses thereof | 伊莱利利公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11926827-B2 | MAPT RNA interference agents | ELI LILLY AND COMPANY (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230340482-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| WO-2023177972-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230212576-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2023-07-06 | — | — | US | disclosed |
| WO-2023114700-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114700-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | SARNP, SARM1, SMN1; SMN2 | MDM2 2053/4885MDM4 4241/4885TP53 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.